ACE-031 – 1mg – Super Human Peptides

ACE-031 – 1mg

Description

Description

ACE-031 (Ramatercept) is a recombinant fusion protein combining the extracellular domain of the activin type IIB receptor (ActRIIB) with the Fc region of human IgG1. Acting as a decoy receptor, it intercepts myostatin and related TGF-β ligands before they can signal muscle cells to restrict growth. Phase 1 studies reported lean mass and muscle volume gains from a single dose. Currently for research use only.

PURITY

99% HPLC

RUO

Research Use Only
Not for human or veterinary use.

Price: $100.00

Myostatin Ligand Trap — Functions as a circulating decoy receptor that binds and neutralizes myostatin and related growth inhibitors (activins, BMPs) before they reach muscle tissue, effectively removing the body’s primary biological brake on skeletal muscle development.
Clinically Documented Muscle Growth — Phase 1 trials in healthy subjects reported approximately 3.3% lean body mass gain and 5.1% increase in quadriceps volume within just 29 days following a single dose — without any exercise intervention.
Broad Anabolic Signaling Pathway Coverage — Unlike targeted myostatin antibodies, ACE-031 blocks multiple members of the TGF-β superfamily simultaneously, inhibiting Smad2/3 phosphorylation and the ERK1/2 atrophy pathway across both slow-twitch and fast-twitch muscle fiber types.
Bone & Metabolic Research Applications — Beyond muscle, ACE-031 has shown preclinical implications for skeletal remodeling, oxidative metabolism optimization (via PGC-1α and PPARβ upregulation), and conditions of muscle wasting such as Duchenne muscular dystrophy and sarcopenia — though clinical development was paused due to vascular side effects.